Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433549 | 0.85 | TPSAB1 (0.39) | ITGB3ITGA2B | |
| SCHEMBL7876014 | 0.84 | TPSAB1 (0.52) | ITGB3ITGA2B | |
| SCHEMBL3833697 | 0.83 | SLC6A1 (0.42) | ITGB3ITGA2BANPEPENPEPSLC6A1 | |
| Hydrochloric Acid SCHEMBL11076520 | 0.82 | TPSAB1 (0.51) | ITGB3ITGA2B | |
| SCHEMBL13611685 | 0.82 | AKR1C3 (0.43) | ITGB3ITGA2B | |
| SCHEMBL30684623 | 0.80 | ITGB3 (0.46) | ITGB3ITGA2B | |
| SCHEMBL2422675 | 0.79 | EPHX2 (0.42) | ITGB3ITGA2BSLC6A1GABRA5GABRB2 | |
| SCHEMBL20003158 | 0.79 | ITGB3 (0.40) | ITGB3ITGA2BANPEPENPEPSLC6A1 | |
| SCHEMBL17275234 | 0.79 | ALDH1A1 (0.43) | ITGB3ITGA2BANPEPENPEPSLC6A1 | |
| SCHEMBL14266466 | 0.79 | GAA (0.39) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930589-A | Tricyclic compound, pharmaceutical composition and application | 广州国家实验室 | 2025-05-06 | — | — | CN | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018064356-A1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | CELGENE INTERNATIONAL II SARL (CH) | 2018-04-05 | — | — | WO | disclosed |
| WO-2015066515-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-7485645-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485645-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1572299-B1 | 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080004248-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-7271175-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271175-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1140909-B1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6432959-B1 | ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1140909-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039119-A1 | NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004248-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | HSD17B3, HSD17B1, HSD17B11 | ITGB3 2116/4885ITGA2B 3770/4885ANPEP 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.